STOCK TITAN
  1. Home
  2. News
  3. INFI

Infinity Pharmaceuticals Inc. - INFI STOCK NEWS

Welcome to our dedicated news page for Infinity Pharmaceuticals (Ticker: INFI), a resource for investors and traders seeking the latest updates and insights on Infinity Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Infinity Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Infinity Pharmaceuticals's position in the market.

News
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
Rhea-AI Summary
Infinity Pharmaceuticals announces actions to reduce burn rate and maximize value of eganelisib after termination of merger agreement. The company plans to seek a strategic transaction and retain SSG Capital Advisors. Measures include a reduction in workforce, board size, and potential delisting from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
Rhea-AI Summary
Infinity Pharmaceuticals terminates merger agreement with MEI Pharma and explores strategic alternatives to maximize value. Infinity will continue developing eganelisib and plans to initiate a Phase 2 clinical trial in head and neck squamous cell carcinoma. The company believes eganelisib offers a near-term value creation opportunity and intends to engage strategic advisors. Infinity is entitled to reimbursement of $1,000,000 in expenses and fees from MEI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.91%
Tags
acquisition
-
News
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP) reminds shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) in connection with the special meeting on July 23, 2023. Independent leading proxy advisory firms ISS and Glass Lewis recommend shareholders vote FOR the transaction. The combined company is well capitalized to advance three differentiated clinical-stage therapeutic development pipelines, creating opportunities for shareholders to benefit from near-term value creation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
News
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
Rhea-AI Summary
MEI Pharma encourages shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, creating a combined company with a diversified pipeline of three clinical-stage development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
acquisition
-
News
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP) reminds shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) in connection with the upcoming special meeting on July 14, 2023. Leading proxy advisory firms, ISS and Glass Lewis, recommend MEI shareholders vote FOR the Infinity transaction, recognizing its strategic benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
acquisition
News
Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
none
-
News
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
Rhea-AI Summary
Glass Lewis and ISS recommend MEI Pharma shareholders to vote for the Infinity transaction. MEI Pharma encourages shareholders to follow the recommendations and highlights the potential benefits of the combined company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
acquisition
-
News
ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
News
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
none
Stock INFI logo
Infinity Pharmaceuticals Inc.

Nasdaq:INFI

INFI Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

INFI Stock Data

726.09k
81.91M
2.36%
23.49%
2.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About INFI

the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business